The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | What are the challenges to using radiology for lung cancer in the clinic?
Aslaug Helland, MD, PhD, University of Oslo, Oslo, Norway, comments on the limitations of radiology in clinics, suggesting that alternative methods for detecting and following up on patients with lung cancer may be worth exploring, but further study is needed to determine their effectiveness and feasibility. Prospective trials are needed to evaluate the limitations of these methods and assess their potential as a viable alternative to radiology. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Radiology is a bottleneck in many clinics today, and other methods to detect or to do the follow-up of patients might be a good option, but it’s too early to say if it’s good enough or if it’s possible. In addition, it’s so far an expensive method, and we need to evaluate the methods and what limits them, so it needs to be studied in a prospective trial...
Radiology is a bottleneck in many clinics today, and other methods to detect or to do the follow-up of patients might be a good option, but it’s too early to say if it’s good enough or if it’s possible. In addition, it’s so far an expensive method, and we need to evaluate the methods and what limits them, so it needs to be studied in a prospective trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding – AstraZeneca (Inst); Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Illumina (Inst); InCyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)
